Healthcare / Drug Manufacturers - GeneralNYSE
$49.46
-1.08 (-2.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.4B · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$99.2B
P/E
13.0x
↓EV/EBITDA
11.2x
↓ROE
34.9%
↑Gross Margin
72.4%
↑Debt/Equity
1.08
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.7%
FCF CAGR
-2.6%
FCF margin
14.6%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.67B · net income $5.72B · FCF $4.76B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.67B | $32.67B | $31.38B | $30.33B | $29.32B |
| Net Income | $5.72B | $5.72B | $2.58B | $4.93B | $14.96B |
| EBITDA | $10.40B | $10.40B | $6.67B | $9.08B | $8.60B |
| EPS | 2.78 | 2.78 | 1.24 | 2.40 | 7.32 |
| Gross Margin | 72.4% | 72.4% | 71.2% | 71.8% | 67.4% |
| Operating Margin | 25.5% | 25.5% | 17.7% | 24.2% | 22.9% |
| Net Margin | 17.5% | 17.5% | 8.2% | 16.2% | 51.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.08 | 1.08 | 1.24 | 1.35 | 1.98 |
| Current Ratio | 0.79 | 0.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.76B | $4.76B | $3.57B | $4.42B | $5.14B |
| Returns | |||||
| ROE | 34.9% | 34.9% | 18.8% | 36.9% | 141.1% |
| Valuation | |||||
| P/E | 12.98 | 12.98 | 26.91 | 16.35 | 4.77 |
| EV/EBITDA | 11.19 | 11.19 | 12.39 | 10.55 | 10.32 |
| P/B | 6.22 | 6.22 | 5.07 | 6.04 | 6.73 |
| Growth & Yield | |||||
| Revenue Growth | 4.1% | 4.1% | 3.5% | 3.4% | — |
| EPS Growth | 123.2% | 123.2% | -48.1% | -67.3% | — |
| Dividend Yield | 3.6% | 3.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.5%
EPS terminal req.
$4.39
Spread vs growth
106.7%
5Y implied EPS CAGR
13.9%
EPS terminal req.
$5.31
Spread vs growth
109.3%
10Y implied EPS CAGR
11.9%
EPS terminal req.
$8.55
Spread vs growth
111.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.1%
Start / end P/E
33.0x → 17.8x
EPS bridge
1.24 → 2.78
Residual
-56.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.